Co-diagnostics, INC 8-K filings

Co-Diagnostics announced its second quarter 2026 financial results, highlighting progress in manufacturing, global clinical trials, and regulatory submissions, alongside a $3.0 million private placement.

Co-Diagnostics, Inc. has entered into an agreement to induce holders of existing warrants to exercise them for cash, in exchange for issuing new warrants, aiming to raise approximately $2.67 million.

Co-Diagnostics, Inc. has amended its equity distribution agreement with Maxim Group LLC, removing the fixed aggregate dollar limitation on future stock sales.

Co-Diagnostics, Inc. announced a $3.0 million private placement of common stock and warrants, aiming to bolster general corporate purposes and working capital.

Co-Diagnostics announced its first quarter 2026 financial results, highlighting regulatory progress in India, expanded distribution in South Asia, and continued investment in R&D.

Co-Diagnostics, Inc. announced full year 2025 financial results, reporting a significant revenue decline and increased net loss, while highlighting progress in global joint ventures and clinical pipeline.

Co-Diagnostics, Inc. received notice from Nasdaq regarding the delisting of its common stock due to non-compliance with the minimum bid price rule, with trading suspension effective January 14, 2026.

Co-Diagnostics, Inc. will implement a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Co-Diagnostics, Inc. shareholders approved a proposal to amend the company's Articles of Incorporation to effect a reverse stock split.

Co-Diagnostics, Inc. announced its third quarter 2025 financial results, reporting a significant revenue decrease but improved net loss, alongside strategic initiatives including a new KSA joint venture and an AI business unit.

Co-Diagnostics, Inc. announced a registered direct offering of common stock and pre-funded warrants, raising approximately $7.0 million for working capital and general corporate purposes.

Co-Diagnostics, Inc. has established a new at-the-market equity offering program to sell up to $10 million of common stock through Maxim Group LLC, replacing a prior agreement.

Co-Diagnostics, Inc. announced its participation in the virtual Lytham Partners Fall 2025 Investor Conference, featuring a webcast presentation and one-on-one meetings.

Co-Diagnostics, Inc. has entered into a securities purchase agreement with institutional investors for a registered direct offering of 9.6 million common shares, expected to generate approximately $3.8 million in gross proceeds.

Co-Diagnostics, Inc. announced its second quarter 2025 financial results, reporting a significant revenue decline but progress on its Co-Dx PCR platform clinical evaluations.

Co-Diagnostics, Inc. has been granted an additional 180-day grace period by NASDAQ until January 5, 2026, to regain compliance with the $1.00 minimum bid price requirement, following its failure to meet the initial compliance deadline.

Co-Diagnostics, Inc. announced the results of its 2025 annual meeting of shareholders, where all nominated directors were re-elected and key proposals, including the 2025 Equity Incentive Plan and executive compensation, were approved.

Co-Diagnostics, Inc. announced its financial results for the first quarter of 2025, reporting a decrease in revenue but highlighting progress in its test pipeline and facility development.

Co-Diagnostics amends its equity distribution agreement to include Clear Street LLC as a sales agent, potentially offering up to $17,111,650 in common stock.

Co-Diagnostics, Inc. announced its full year 2024 financial results, highlighting a revenue decrease due to reduced grant revenue, alongside progress in its diagnostic test pipeline and regulatory submissions.

Co-Diagnostics withdraws its 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro following FDA feedback, opting to submit an enhanced version for clearance.

Co-Diagnostics, Inc. (CODX) received a notice from Nasdaq on January 10, 2025, indicating that its common stock price has fallen below the minimum $1.00 per share required for continued listing.

Co-Diagnostics Inc. has amended its previous 8-K filing to disclose that it will conduct annual Say-on-Pay votes following a shareholder vote at its 2024 Annual Meeting.

Co-Diagnostics reported a revenue decline in Q3 2024, primarily due to the timing of grant revenue recognition, alongside an increased net loss compared to the previous year.

Co-Diagnostics, Inc. held its 2024 annual meeting, electing a director, approving executive compensation, and ratifying the appointment of its accounting firm.

Co-Diagnostics saw a significant increase in revenue and reduced operating losses in Q2 2024, driven by grant milestones and lower expenses, while also submitting a key FDA application.

Co-Diagnostics has submitted its first FDA 510(k) application for its Co-Dx PCR Pro platform and COVID-19 test for over-the-counter use.

Co-Diagnostics reported a decrease in revenue and an increased net loss for the first quarter of 2024, alongside strategic expansions and leadership changes.

Co-Diagnostics, Inc. has appointed Richard Abbott as President, effective March 15, 2024.

Co-Diagnostics reported a significant decrease in revenue for 2023 due to reduced demand for COVID-19 tests, alongside increased investment in new platform development.